FDA approves production of Shire drug in Lexington

Shire, an Irish drug company with about 1,400 employees in Lexington, said Friday it has received US regulatory approval to make the Gaucher disease drug Vpriv at its manufacturing facility there.

The facility was previously approved by European regulators for the production of Vpriv. Gaucher disease is a rare genetic disorder.

Shire PLC said it has invested more than $200 million in manufacturing infrastructure and technology to establish a consistent drug supply chain to patients.


The company also has a facility in the Alewife neighborhood of Cambridge.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

Vpriv has been approved in more than 40 countries.

Chris Reidy